The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2021 | Transplantation with alternative donors in myelofibrosis
Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, compares outcomes for patients with myelofibrosis, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), who receive transplantation with an alternative donor. Prof. Kröger reports that an HLA-identical sibling is still the preferred donor for patients with myelofibrosis. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
